COCP News and Press, Cocrystal Pharma Inc. From 11/12/19

– Following new positive data from Phase 2a study, Company outlines next steps in clinical development plan for lead program CC-31244 for ultrashort treatment of hepatitis C (HepC) –  – Preclinical influenza A/B program fully-funded by development and commerci...

- New data presented at the American Association for the Study of Liver Diseases (AASLD) 2019 Liver Meeting - - Patients that achieved SVR had significantly higher frequencies of terminally differentiated effector memory CD8+ T cells compared with those who relapsed - - Deve...

Gainers:  Communications Systems (NASDAQ: JCS ) +27% . Zovio (NASDAQ: ZVO ) +19% . CRA International (NASDAQ: CRAI ) +19% . PolarityTE (NASDAQ: PTE ) +18% . Ducommun Incorporated (NYSE: DCO ) +17% . Murphy USA (NYSE: MUSA ) +17% . Dawson Geophysical (NASDAQ: DWSN ) +17% . EyeGa...

Ultra-thinly traded nano cap Cocrystal Pharma ( COCP -34.4% ) is down on a 25x surge in volume, albeit on turnover of only 340K shares, in response to its public offering of ~3.5M common shares at $0.85 per share. More news on: Cocrystal Pharma, Inc., Healthcare stocks news, Stocks on ...

BOTHELL, WA, Oct. 31, 2019 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”) , a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced the pricing of an...

BOTHELL, WA, Oct. 30, 2019 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”) , a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced it intends to off...

New data to be presented from U.S. Phase 2a clinical trial of CC-31244 for ultrashort treatment of hepatitis C virus (HCV) Eight of 12 patients achieved primary endpoint of sustained virologic response (SVR) 12, which is considered a cure, using only 6 weeks of Epclusa’s therapy...

Gainers:  NF Energy Saving Corporation (NASDAQ: BIMI ) +33% . PetMed Express (NASDAQ: PETS ) +27% . Quintana Energy Services (NYSE: QES ) +18% . Seattle Genetics (NASDAQ: SGEN ) +15% . NanoViricides (NYSEMKT: NNVC ) +15% . BioNTech SE (NASDAQ: BNTX ) +14% . Flexible Solutions In...

- Novel class of HCV antivirals targeting the NS3 helicase that can be studied for the treatment of chronic HCV infection developed utilizing Company’s unique structure-based drug design platform technology - BOTHELL, WA, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, I...

BOTHELL, WA, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that Sam Lee, Ph.D., Pre...